OR WAIT 15 SECS
Click here to read the articles and download the PDF
Deeply shaped by the experiences of his parents and an early charge to help drive social change, Global Blood Therapeutics’ Ted Love comes at sickle cell disease from a place of caring and urges pharma to follow suit to bring justice to all.
With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.
Click for more information
A recent roundtable moderated by Rob Jekielek of The Harris Poll gathered five biopharma CEOs to discuss the industry’s shifting reputational landscape in the public eye.
Samit Hirawat, chief medical officer at Bristol Myers Squibb, talks about his leading role in BMS’ $300M, five-year plan to expand its efforts in health equity and his career-long commitment to putting patients first.
Highlighted Videos
January 18, 2021
How engaging with digital influencers holds the key for medical affairs.
January 15, 2021
Sameer Lal and Sandeep Gantotti discuss the building of a next-gen medical information practice to modernize its operations and unlock its value to the wider organization and to HCPs.
January 14, 2021
Administration officials continue to rush through new rules and decisions that appear to challenge the independence and effective operations of FDA.
How biopharma manufacturers can address extreme pricing of novel rare disease medicines and build legitimacy into commercialization to avoid an industrywide crisis.
Data suggests physicians just as hesitant as patients, but recent successes could turn the tide.
January 13, 2021
Industry’s tardy shift to cloud-based solutions looks set to gather pace in 2021.
Biopharma sustainability resolutions for a better 2021.
January 12, 2021
On December 24, 2020, the UK finally agreed a Trade and Cooperation Agreement (TCA) with the EU. Cliodhna McDonough offers some initial thoughts on the implications of the TCA on the life sciences sector.
